Compare HTGC & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTGC | LQDA |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.8B |
| IPO Year | 2004 | 2020 |
| Metric | HTGC | LQDA |
|---|---|---|
| Price | $16.41 | $43.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 8 |
| Target Price | $19.50 | ★ $54.38 |
| AVG Volume (30 Days) | 1.0M | ★ 5.2M |
| Earning Date | 10-29-2026 | 11-06-2026 |
| Dividend Yield | ★ 11.46% | N/A |
| EPS Growth | 14.91 | ★ 51.81 |
| EPS | 0.90 | ★ 1.26 |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $9.32 | $357.27 |
| Revenue Next Year | $7.07 | $1.34 |
| P/E Ratio | ★ $18.19 | $33.88 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $13.70 | $22.05 |
| 52 Week High | $19.13 | $93.61 |
| Indicator | HTGC | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 44.57 | 50.31 |
| Support Level | $16.09 | $35.00 |
| Resistance Level | $17.05 | $46.67 |
| Average True Range (ATR) | 0.27 | 2.98 |
| MACD | 0.01 | 2.63 |
| Stochastic Oscillator | 58.61 | 93.07 |
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.